Moderna, Inc.
NasdaqGS-MRNA
Company Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Name
Moderna, Inc.
CEO
Mr. Stephane Bancel
Website
www.modernatx.com
Sector
Biotechnology
Year Founded
2010
Profile
Market Cap
$26.85B
EV
$17.31B
Shares Out
384.4M
Revenue
$5,050M
Employees
5,600
Margins
Gross
-62.99%
EBITDA
-81.33%
Operating
-91.78%
Pre-Tax
-85.78%
Net
-116.18%
FCF
-78.79%
Returns (5Yr Avg)
ROA
8.99%
ROTA
21.64%
ROE
21.65%
ROCE
24.34%
ROIC
0.21%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$99.84
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$8,488M
Net Debt
-$9,545M
Debt/Equity
0.11
EBIT/Interest
-165.54
Growth (CAGR)
Rev 3Yr
-10.39%
Rev 5Yr
116.45%
Rev 10Yr
—
Dil EPS 3Yr
21.94%
Dil EPS 5Yr
45.6%
Dil EPS 10Yr
—
Rev Fwd 2Yr
-29.64%
EBITDA Fwd 2Yr
-67.53%
EPS Fwd 2Yr
-72.29%
EPS LT Growth Est
-24.58%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—